[1]徐翠香a,靳占奎b,王 曦,等.Luminex技术检测肾移植患者血清IL-17预测急性排斥反应的回顾性研究徐翠香,[J].现代检验医学杂志,2017,32(04):87-90.[doi:10.3969/j.issn.1671-7414.2017.04.024]
　XU Cui-xianga,JIN Zhan-kuib,WANG Xi,et al.Retrospective Study of Detection of Serum IL-17 for Predicting Early Acute Renal Allograft Rejection by Luminex Technique[J].Journal of Modern Laboratory Medicine,2017,32(04):87-90.[doi:10.3969/j.issn.1671-7414.2017.04.024]
点击复制

Luminex技术检测肾移植患者血清IL-17预测急性排斥反应的回顾性研究徐翠香,()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年04期
页码:
87-90
栏目:
论著
出版日期:
2017-07-25

文章信息/Info

Title:
Retrospective Study of Detection of Serum IL-17 for Predicting Early Acute Renal Allograft Rejection by Luminex Technique
文章编号:
1671-7414(2017)04-087-04
作者:
徐翠香1a; 靳占奎1b; 王 曦2; 杨 乐3; 韩峰4; 段万里1c; 田普训4
1.陕西省人民医院a.陕西省临床检验中心; b.骨科; c.泌尿外科,西安 710068; 2.西安市红会医院,西安 710054; 3.西安市儿童医院,西安 710003; 4.西安交通大学第一附属医院肾脏病医院肾移植科,西安 710061
Author(s):
XU Cui-xiang1a; JIN Zhan-kui1b; WANG Xi2; YANG Le3; HAN Feng4; DUAN Wan-li1c; TIAN Pu-xun4
1a.Shaanxi Provincial Center for Clinical Laboratory; 1b.Department of Orthopedics; 1c.Department of Urology,Shaanxi Provincial People's Hospital,Xi'an 710068,China; 2.Xi'an Honghui Hospital,Xi'an 710054,China; 3.Xi'an Children's Hospital, Xi'an 710003,China; 4.Department of Kidney Transplantation,Hospital ofNephropathy, First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China
关键词:
肾移植;  IL-17;  急性排斥反应
分类号:
R699.2; R392.11
DOI:
10.3969/j.issn.1671-7414.2017.04.024
文献标志码:
A
摘要:
目的 应用Luminex液相芯片技术检测肾移植患者血清IL-17的表达水平,探讨其与移植肾早期急性排斥反应的关系。方法 选取2009年1月～2011年10月期间38例肾移植患者和20例健康对照者; 根据预后将肾移植患者分为急性排斥组(18例)和非排斥组(20例),分别检测两组肾移植患者及健康对照者血清IL-17的表达情况,分析血清IL-17与移植肾患者发生急性排斥反应的相关性。结果肾移植患者术前血清IL-17的平均水平为1.3±1.9 pg/ml,显著低于健康对照组(6.9±8.5 pg/ml),差异有统计学意义(t=3.968,P<0.001); 肾移植患者急性排斥组血清在术后第7天IL-17水平为3.4±5.8 pg/ml,高于非排斥组(0.5±0.4 pg/ml),差异有统计学意义(t=2.242,P=0.031)。Kaplan-Meier法生存分析显示肾移植术后非排斥反应患者血清IL-17高值水平的生存率显著低于低值水平(P<0.001)。ROC曲线显示,将肾移植患者术后第4天与第7天血清IL-17水平联合分析,预测其急性排斥反应的灵敏度和特异度分别为66.67%和100%。结论 肾移植患者术后4～7天血清IL-17水平的动态升高趋势可预测其早期急性排斥反应发生的可能性。
Abstract:
Objective To detect the expression of IL-17 inrenal transplant recipients by Luminex and evaluate the relationship between the level of serum IL-17 and early acute renal allograft rejection.Methods 38 kidney transplant recipients and healthy controls(HC,healthy volunteers,n=20)were selected in this study from January 2009 to October 2011.All patients were divided into two groups according to their allograftoutcome as acute rejection group(ARG,n=18)and non-rejection group(NRG,n=20).The expression of serum IL-17 was detected by Luminex technique in two groups of kidney transplant recipients and HC.To evaluate the correlation between the level of serum IL-17 and early acute renal allograft rejection.Results The mean level of IL-17 in all renal transplant recipients 1.3±1.9 pg/ml at the pre-transplantation was significantly lower than that in HC(6.9±8.5 pg/ml,t=3.968,P<0.001).The results highlightedthat the level of serum IL-17 in ARG 3.4±5.8 pg/ml was significantly higher than that in NRG(0.5±0.4 pg/ml)on the 7th days post Kidney transplantation(post-KTx,t=2.242,P=0.031). Kaplan-Meier survival analysis showed that the probability of rejection-free survival in the higher levels group ofIL-17 on the 7th days post-KTx was significant lower than that in the lower levels group(P<0.001).The results of receiver operating characteristic curve showed that the sensitivity and specificity of the combined IL-17 to predictacute rejection were 66.67% and 100%,respectively.Conclusion The serum IL-17 levels in renal transplant recipients on the 4th and 7th post-KTx days can predict early renal transplant rejection.

参考文献/References:

[1] Buyse M,Sargent DJ,Grothey A,et al.Biomarkers and surrogate end points-the challenge of statistical validation[J].Nature Reviews ClinicalOncology,2010,7(6):309-317.
[2] Jafari A,Khatami MR,Dashti-Khavidaki S,et al.Plasma neutrophil gelatinase-associated lipocalin as a marker for prediction of 3-month graft survival after kidney transplantation[J].Int J Organ Transplant Med,2017,8(1):17-27.
[3] Faust SM,Lu G,Marini BL,et al.Role of T cell TGF beta signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection[J].J Immunol,2009,183(11):7297-7306.
[4] 黎磊石.排斥反应的诊断和治疗[M].//朱同玉.中国肾移植手册,香港:华夏科学出版社,2009:195.
[5] Heidt S,San Segundo D,Shankar S,et al.Peripheral blood sampling for the detection of allograft rejection:biomarker identification and validation[J].Transplantation,2011,92(1):1-9.
[6] Kim N,Yoon YI,Yoo HJ,et al.Combined detection of serum IL-10,IL-17,and CXCL10 predicts acute rejection following adult liver transplantation[J].Mol Cells,2016,39(8):639-644.
[7] Li T,Si Z,Qi H,et al.IL-17 in the early diagnosis of acute renal allograft rejection in mice[J].Journal of Central South University Medical Sciences,2011,36(12):1147-1152.
[8] Van Kooten C,Boonstra JG,Paape ME,et al.Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection[J].J Am Soc Nephrol,1998,9(8):1526-1534.
[9] Antonysamy MA,Fanslow WC,Fu F,et al.Evidence for a role of IL-17 inorgan allograft rejection:IL-17 promotes the functional differentiation of dendritic cell progenitors[J].J Immunol,1999,162(1):577-584.
[10] Duan L,Chen J,Xia Q,et al.IL-17 promotes Type 1 T cell response through modulating dendritic cell function in acute allograft rejection[J].Int Immunopharmacol,2014,20(2):290-297.
[11] Kimura N,Nakae S,Itoh S,et al.Potential role of gamma delta T cell-derived IL-17 in acute cardiac allograft rejection[J].Ann Thorac Surg,2012,94(2):542-548.
[12] Witowski J,Ksiazek K,Jorres A.Interleukin-17:a mediator of inflammatory responses[J].Cell Mol Life Sci,2004,61(5):567-579.
[13] Loong CC,Hsieh HG,Lui WY,et al.Evidence for the early involvement ofinterleukin 17 in human and experimental renal allograft rejection[J].J Pathol,2012,228(2):260.
[14] Zheng HL,Shi BY,Du GS,et al.Changes in Th17 and IL-17 levels duringacute rejection after mouse skin transplantation[J].Eur Rev Med Pharmacol Sci,2014,18(18):2720-2786.
[15] Vanaudenaerde BM,Dupont LJ,Wuyts WA,et al.The role of interleukin-17 during acute rejection after lung transplantation[J].Eur Respir J,2006,27(4):779-787.
[16] Tesar BM,Du W,Shirali AC,et al.Aging augments IL-17 T-cell alloimmune responses[J].Am J Transplant,2009,9(1):54-63.
[17] 王朝晖,李玉中,王增凯.Th17细胞及白细胞介素-17在肝移植急性排斥反应中的意义[J].中国微生态学杂志,2014,26(5):567-570. Wang ZH,Li YZ,Wang ZK.Significance of Th17 and IL-17 to acute rejection following liver transplantation[J].Chinese Journal of Microecology,2014,26(5):567-570.
[18] Lindemann M,Konemann J,Horn PA,et al.IL-17 ELISpot as predictor forkidney allograft rejection?[J].Clin Lab,2016,62(5):963-965.
[19] Mehrotra S,Sharma RK,Mayya M,et al.Luminex solid-phase crossmatch for de novo donor-specific antibodies in living-donor related transplants[J].Exp Clin Transplant,2017.
[20] Ducreux S,Guillaud O,Bosch A,et al.Monitoring efficiency of humoralrejection episode therapy in liver transplantation: any role for complement binding Luminex Single Antigen assays?[J].Transpl Immunol,2016(35):23-28.

相似文献/References:

[1]王坤英,张蓬杰a,王慧英,等.肾移植术后肺部感染时间、病原菌分布及耐药性分析[J].现代检验医学杂志,2016,31(05):97.[doi:10.3969/j.issn.1671-7414.2016.05.026]
　WANG Kun-ying,ZHANG Peng-jiea,WANG Hui-ying,et al.Analysis of the Onset Time,Pathogen Distribution and Drug Resistance in Kidney Transp-Lant Patients with Lung Infection[J].Journal of Modern Laboratory Medicine,2016,31(04):97.[doi:10.3969/j.issn.1671-7414.2016.05.026]
[2]魏菁菁,王冬梅,胡　俊,等.肾移植术后患者血液他克莫司代谢率(C0/D 值) 对肝肾功能的影响研究[J].现代检验医学杂志,2020,35(03):112.[doi:10.3969/j.issn.1671-7414.2020.03.030]
　WEI Jing-jing,WANG Dong-mei,HU Jun,et al.Metabolic Rate of Tacrolimus(C0/D ratio) and the Effects on Hepatic Function Renal Function after Renal Transplantation[J].Journal of Modern Laboratory Medicine,2020,35(04):112.[doi:10.3969/j.issn.1671-7414.2020.03.030]
[3]王坤英a,张蓬杰,王剑茹b,等.肾移植受者早期血清25- 羟基维生素D 水平对急性排斥反应的预测价值研究[J].现代检验医学杂志,2024,39(04):138.[doi:10.3969/j.issn.1671-7414.2024.04.025]
　WANG Kunyinga,ZHANG Pengjie,WANG Jianrub,et al.Study on the Predictive Value of Serum 25-Hydroxyvitamin D Level in Early Renal Transplantation for Acute Rejection[J].Journal of Modern Laboratory Medicine,2024,39(04):138.[doi:10.3969/j.issn.1671-7414.2024.04.025]

备注/Memo

备注/Memo:
作者简介:徐翠香(1980-),女,在读博士,主治医师,主要从事移植免疫学研究,E-mail:xucuixiang1129@163.com。 通讯作者:靳占奎(1982-),男,博士,主治医师,E-mail:zhankui999@163.com。
更新日期/Last Update: 1900-01-01